Management and Outcomes of Type I and Type II Myocardial Infarction in Cardiogenic Shock.

ABSTRACT:

Background

Type I myocardial infarction (T1MI) or type II myocardial infarction (T2MI) have different underlying mechanisms; however, in the setting of cardiogenic shock (CS), it is not understood if patients experience resultantly different outcomes. The objective of this study was to determine clinical features, biomarker patterns, and outcomes in these subgroups.

Methods

Patients from the CAPITAL-DOREMI trial presenting with acute myocardial infarction-associated CS (n = 103) were classified as T1MI (n = 61) or T2MI (n = 42). The primary endpoint was a composite of all-cause in-hospital mortality, cardiac arrest, the need for mechanical circulatory support, or initiation of renal replacement therapy at 30 days. Secondary endpoints were evaluated as individual components o

SUBMITTER: Stotts C 

PROVIDER: S-EPMC11780372 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature